Skip to main content
  • CSIR and Tata MD partners to augment COVID-19 testing

    The Council for Scientific and Industrial Research (CSIR), and Tata Medical and Diagnostics Ltd (Tata MD), the new healthcare venture from the Tata Group have teamed up to boost the COVID-19 testing capacity across Tier-II and Tier-III towns as well as rural areas, across India. The two organisations are developing capacity to handle any future surge in the COVID-19 testing requirements.

    admin Mon, 06/21/2021 - 16:43
  • AI-driven XraySetu to facilitate early COVID detection

    A new AI-driven platform will now help early intervention through rapid screening of COVID 19 with the help of Chest X-ray interpretation over WhatsApp for doctors who have access to X-ray machines. The solution called XraySetu can work with low-resolution images sent via mobiles, is quick and easy to use, and can facilitate detection in rural areas.

  • BRICS meeting deliberated on emerging issues in Biotechnology and Biomedicine

    Experts deliberated on emerging issues in the various fields of Biotechnology and Biomedicine at the fourth BRICS Working Group meeting on the subject area.

    More than 60 participants, including researchers, academicians, and government officials participated from all five BRICS countries Brazil, Russia, India, China, and South Africa, participated in the online meeting organized from May 25 to May 26 2021.

  • Indian Immunologicals Limited to start production of drug substance for Covaxin under Mission COVID Suraksha

    In a bid to augment the vaccine production, the Government has decided to support some public sector companies with grants under the Mission COVID Suraksha. One such company is the Hyderabad based Indian Immunological limited (IIL), which a facility under the PSU, National Dairy Development Board.

  • Government decides to discontinue the Central Allocation of Remdesivir

    Minister of State  for Chemicals and Fertilizers Shri Mansukh Mandaviya informed that the production of Remdesivir is ramped up ten times from 33,000 vials/day on 11th April 2021 to 3,50,000 vials/day today.

    The Minister further informed that the Government has also increased the number of plants producing Remdesivir from 20 to 60 plants within a month. Now the country has enough Remdesivir as the supply is much more than the demand, he added.

  • First self testing Rapid test for COVID-19 approved by ICMR

    Mylab Discovery Solutions announced the first self use Rapid test of India, Coviself which is approved by ICMR. Each Coviself test kit will be provided with all testing materials, instructions to use leaflet and a biohazard bag to safely dispose of after testing. It is available at economical pricing of Rs 250. Last year, Mylab launched the first RTPCR test of India for COVID-19.

  • IISc start-up gets regulatory approvals for COVID-19 test

    PathShodh Healthcare, a start-up incubated at the Society for Innovation and Development (SID), Indian Institute of Science (IISc), has made a significant breakthrough in developing a first-of-its-kind, semi-quantitative electrochemical ELISA test for COVID-19 IgM and IgG antibodies.

  • Government take steps to ramp up availability of Amphotericin B - to fight Mucormycosis

    A sudden increase in demand has been observed in some states for Amphotericin B which is being actively prescribed by the physicians to patients suffering from Mucormycosis, a post COVID complication. The Government of India is therefore engaging with the manufacturers to ramp up production of the drug. The supply position is expected to improve with extra  imports of this drug and  increase in its production domestically.

  • One of the Worlds Largest Healthcare Projects with 5000 NHS-Standard Clinics and 11 Medicities Gets Started

    Indo UK Clinics an integral part of one of the largest healthcare projects in the world encompassing 5000 clinics and 11 medicities pan-India using NHS expertise, equipment and suppliers gets started with first Indo UK Clinic becoming operational in Ludhiana, Punjab. The objective of setting up 5000 diagnostic centers and clinics is a part of inter-governmental discussions between India and the UK at Commonwealth Heads of Government Meeting (CHOGM) level in 2018.

  • AYUSH 64 found useful in the treatment of mild to moderate COVID-19 infection

    In the middle of the havoc wreaked by second wave of the pandemic, AYUSH-64 has emerged as a ray of hope for the patients of mild and moderate COVID-19 infection. The scientists of reputed research institutions of the country have found that AYUSH 64, a poly herbal formulation developed by the Central Council for Research in Ayurvedic Sciences (CCRAS), Ministry of Ayush is useful in the treatment of asymptomatic, mild and moderate COVID-19 infection as an adjunct to standard care.

    admin Fri, 04/30/2021 - 14:36
Subscribe to Government News

Search this website